This invention concerns compounds of formula ##STR1## the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein R.sup.1 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, C.sub.1-6 alkylthio, amino, mono- or di(C.sub.1-6 alkyl)amino, Ar.sup.1, Ar.sup.1 --NH--, C.sub.3-6 cycloalkyl, hydroxymethyl or benzyloxymethyl; R.sup.2 and R.sup.3 are hydrogen, or taken together may form a bivalent radical of formula --CH.dbd.CH--CH.dbd.CH--; R.sup.4, R.sup.5 and R.sup.6 are each independently selected from hydrogen, halo, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, trifluoromethyl, nitro, amino, cyano, azido, C.sub.1-6 alkyloxyC.sub.1-6 alkyl, C.sub.1-6 alkylthio, C.sub.1-6 alkyloxycarbonyl or Het.sup.1 ; or when R.sup.4 and R.sup.5 are adjacent to each other they may be taken together to form a radical of formula --CH.dbd.CH--CH.dbd.CH--; A is a bivalent radical of formula NR.sup.7, NR.sup.7 -Alk.sup.1 -X-, NR.sup.7 -Alk.sup.1 -X-Alk.sup.2 -, O-Alk.sup.1 -X-, O-Alk.sup.1 -X-Alk.sup.2 - or S-Alk.sup.1 -X-; wherein X is a direct bond, --O--, --S--, C.dbd.O, --NR.sup.8 -- or Het.sup.2 ; R.sup.7 is hydrogen, C.sub.1-6 alkyl or Ar.sup.2 methyl; R.sup.8 is hydrogen, C.sub.1-6 alkyl or Ar.sup.2 methyl; Alk.sup.1 is C.sub.1-6 alkanediyl; Alk.sup.2 is C.sub.1-4 alkanediyl; Ar.sup.1 and Ar.sup.2 are optionally substituted phenyl; phenyl; Het.sup.1 and Het.sup.2 are optionally substituted heterocycles; having angiogenesis inhibiting activity; their preparation, compositions containing them and their use as a medicine.